Women's Health Market Report 2025

The women's health market size has grown steadily in recent years. It will grow from $43.53 billion in 2024 to $45.5 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to advancements in reproductive medicine, awareness and education initiatives, empowerment and advocacy movements, prenatal and postnatal care advances, development of hormone replacement therapies.

The women's health market size is expected to see strong growth in the next few years. It will grow to $58.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to precision medicine in gynecology, rise in female-focused clinical trials, expanded use of non-invasive prenatal testing, expanded access to fertility treatments, increasing focus on mental health. Major trends in the forecast period include digital health solutions, fertility tracking and reproductive health, non-hormonal contraceptive options, maternal health and pregnancy monitoring, innovations in women's health diagnostics, integration of artificial intelligence (ai).

The escalating prevalence of women-centric diseases stands as a significant driver propelling the growth trajectory of the women's health market. A surge in conditions such as anemia, osteoporosis, breast cancer, menopause, and others, attributed to diverse risk factors like family history, advancing age, early onset of menstruation or menopause post-55 years, obesity, among others, is fueling the demand for women's health products and services. These offerings cater to treating these diseases while prioritizing the overall health and wellness of women. For example, the American Cancer Society's report published in January 2023 highlighted cervical cancer's historical status as a leading cause of cancer-related deaths among American women. An estimated 13,960 new cases of invasive cervical cancer are projected to be diagnosed in the USA in 2023, with approximately 4,310 anticipated fatalities. Hence, the escalating incidence of women-centric diseases is steering the expansion of the women's health market.

An upsurge in the aging populace emerges as a significant catalyst propelling the advancement of the women's health market. The demographic shift towards an aging population, characterized by a burgeoning proportion of individuals aged 65 and above, necessitates an increased focus on women's health needs. Women within this demographic encounter a higher prevalence of diseases such as osteoporosis, breast cancer, and menopause-related issues. This demographic shift underscores the augmented demand for specialized women's health services and products. It accentuates the significance of preventive measures, screenings, and tailored healthcare interventions aimed at preserving the well-being and enhancing the quality of life for older women. Notably, the World Health Organization's October 2022 report predicts that by 2030, 1 in 6 individuals globally will be aged 60 years or older, with the population of people aged 60 years and older anticipated to double by 2050, reaching 2.1 billion. Thus, the burgeoning aging population significantly propels the women’s health market.

Developments in women's health represent a significant trend within the women's health market. Leading companies in this sector are creating new products to bolster their market position. For example, in July 2022, GE Healthcare, a US-based medical technology firm, introduced the Voluson Expert 22. This new addition to the company’s women's health portfolio utilizes graphic-based beam former technology, providing exceptional image quality and improved flexibility in imaging capabilities. The system is equipped with advanced tools powered by Artificial Intelligence (AI), ensuring greater consistency in examinations while minimizing the number of tasks needed.

Major players in the women’s health market are integrating innovative technologies like Transcutaneous Electrical Nerve Stimulation (TENS) to solidify their position. TENS is a non-invasive therapeutic technique involving a battery-operated device that emits low-voltage electrical currents through electrode pads placed on specific body areas. This technology, exemplified by Myoovi's September 2023 launch in the UK, offers relief for painful menstruation cramps. By generating electrical signals, TENS interferes with and obstructs pain signals attempting to reach the brain, thereby minimizing pain. This drug-free alternative helps women manage the discomfort associated with menstrual cramps, offering a promising solution.

In March 2024, Halma, a UK-based technology firm, acquired Rovers Medical Devices (Rovers) for $92.63 million. This acquisition expands Halma's offerings in the women's health sector, specifically in cervical cancer diagnostics, and supports its objective of enhancing its position in cancer diagnosis products. Rovers Medical Devices, based in the Netherlands, specializes in designing and manufacturing sample collection devices intended for the diagnosis and prevention of cervical cancer.

Major companies operating in the women's health market are AbbVie Inc., Bayer AG, Merck & Co Inc., Pfizer Inc., Agile Therapeutics, Apothecus Pharmaceutical Corporation, Blairex Laboratories Inc., Novartis AG, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Lupin Pharmaceuticals Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Hologic Inc., Celmatix Inc., HERA Biotech Inc., Juno Bio Inc., Maven Clinic Inc., MobileODT Ltd., Mylan N.V., ObsEva SA, Scailyte AG, Syrona Health AG.

North America was the largest region in the women's health market in 2024. Asia-Pacific is expected to be the fastest-growing region in the women's health market report during the forecast period. The regions covered in the women's health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the women's health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Women's health pertains to the area of medicine and healthcare dedicated to diagnosing, treating, and preventing diseases and conditions that uniquely impact women. This field covers various issues, including reproductive health, menstrual health, pregnancy and childbirth, menopause, and conditions like breast and ovarian cancers. It also tackles other health concerns that disproportionately affect women, such as osteoporosis, cardiovascular disease, and autoimmune disorders.

The primary categories of products related to women's health include devices, drugs, and pharmaceutical pipelines. Women's health devices are instrumental in treating medical conditions specific to women. This includes individuals aged 50 years and older, who may undergo hormonal treatment, non-hormonal treatment, and surgeries for a range of applications. These applications span postmenopausal osteoporosis, hormonal infertility, endometriosis, uterine fibroids, contraceptives, menopause, and polycystic ovary syndrome (PCOS). These women's health products are made available through various distribution channels, including hospitals, retail stores, and online pharmacies.

The women’s health market research report is one of a series of new reports that provides women’s health market statistics, including women’s health industry global market size, regional shares, competitors with a women’s health market share, detailed women’s health market segments, market trends and opportunities, and any further data you may need to thrive in the women’s health industry. This women’s health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The women's health market consists of revenues earned by entities by providing hormone therapy, birth control treatment, and other related services. The market value includes the value of related goods sold by the service provider or included within the service offering. The women's health market also includes sales of contraceptive devices and pharmaceuticals, densitometry, breast implants, obstetrics or gynecology biopsy, imaging devices, and drugs such as Xgeva, Evista, Mirena, Zometa, Reclast, and Class, among others, that are used in providing women's health services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.